May 12, 2026 | Congress, Pharma, healthcare
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize the value of congress investment and deliver measurable business impact.

Medical congresses remain one of the most critical data milestones in an asset’s development, providing valuable opportunities to translate scientific innovation into clinical practice. However, many organizations still approach congresses as standalone events, with fragmented planning across therapy area teams, limited alignment to overarching disease area objectives, and limited clarity on measuring success beyond immediate metrics.
By operating as a single, integrated partner across the full data and congress lifecycle, Inizio helps clients navigate complexity, align stakeholders, and gain clearer confidence in the impact of their congress investments. Our strength lies in an unmatched vantage point – combining deep, cross-functional expertise with end-to-end visibility across the product lifecycle.
Intelligent Congress is built on this foundation. Drawing on more than 30 years of experience across therapy areas, it unites strategy, experience design, delivery, and measurement into one cohesive model. This depth and breadth enable clients to move beyond fragmented, activity-based metrics and instead focus on what truly matters – meaningful shifts in HCP understanding, engagement, and behavior.
Discover how Intelligent Congress can help you create more strategic, measurable, and impactful HCP engagement. Visit our congress page or connect with the Inizio team at booth 21157 during the ASCO® Annual Meeting 2026 to see Intelligent Congress in action.
Read full article here.
This content was provided by Inizio
Latest Content from Inizio
Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the Excellence In Integrated Product/Brand Communications award at the 2017 Communiqué awards for its work with…
We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.
Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr…
We recently celebrated our 20th year anniversary with parties for our employees across the globe.Find out more and view the photos https://www.researchpartnership.com/news/2017/06/20th-anniversary-party-photos/
13-14 July 2017, Singapore
We are delighted to announce that Research Partnership’s Richard Head is joint winner of the 2017 EphMRA President’s Award for his contribution to pharmaceutical market research
We are delighted to announce that Forever Angels founder Amy Hathaway has been awarded an MBE in this year’s Queen’s Birthday Honours list for providing interim and community care to…
We are delighted to announce that our Asia-Pacific team in Singapore has relocated to new premises.
Published in eyeforpharma June 2017 by Marc Yates
Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US. The study employs a mixed quantitative/qualitative methodology and will be available to purchase…
